KalVista Pharmaceuticals (KALV) Tops Q1 EPS by 14c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q1 EPS of ($0.74), $0.14 better than the analyst estimate of ($0.88).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• B.Riley Assumes Anika Therapeutics (ANIK) at Buy
• Can global equities keep rising? UBS sees these factors driving upside